134 related articles for article (PubMed ID: 5081018)
1. Precipitation methods in plasma fractionation.
Steinbuch M
Vox Sang; 1972; 23(1):92-106. PubMed ID: 5081018
[No Abstract] [Full Text] [Related]
2. Fractionation of plasma with polyethylene glycol.
Polson A; Ruiz-Bravo C
Vox Sang; 1972; 23(1):107-18. PubMed ID: 5081005
[No Abstract] [Full Text] [Related]
3. The current status of blood fractionation in the United States.
Sgouris JT
Vox Sang; 1972; 23(1):45-55. PubMed ID: 5081014
[No Abstract] [Full Text] [Related]
4. The development of plasma derivatives for clinical use. A symposium summary.
Deutsch HF
Vox Sang; 1972; 23(1):147-50. PubMed ID: 5081010
[No Abstract] [Full Text] [Related]
5. Plasma fractionation in England and Wales.
Vallet L
Vox Sang; 1972; 23(1):58-60. PubMed ID: 4628157
[No Abstract] [Full Text] [Related]
6. Plasma fractionation in the United States. A review for clinicians.
Ness PM; Pennington RM
JAMA; 1974 Oct; 230(2):247-50. PubMed ID: 4137885
[No Abstract] [Full Text] [Related]
7. Blood products.
Med Lett Drugs Ther; 1979 Nov; 21(23):93-6. PubMed ID: 502967
[No Abstract] [Full Text] [Related]
8. Removal of hepatitis B surface antigen (HBsAg) from plasma fractions.
Johnson AJ; Semar M; Newman J; Harris RB; Brandt D; Middleton S; Smith J
J Lab Clin Med; 1976 Jul; 88(1):91-101. PubMed ID: 932537
[TBL] [Abstract][Full Text] [Related]
9. Plasma fractionation methods used in Sweden.
Björling H
Vox Sang; 1972; 23(1):18-25. PubMed ID: 4628155
[No Abstract] [Full Text] [Related]
10. Polyvinylpyrrolidone (PVP): a new precipitating agent for human and bovine factor VIII and fibrinogen.
Casillas G; Simonetti C
Br J Haematol; 1982 Apr; 50(4):665-72. PubMed ID: 6802165
[TBL] [Abstract][Full Text] [Related]
11. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors.
Johnson AJ; Mathews RW; Fulton AJ
Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834
[TBL] [Abstract][Full Text] [Related]
12. [Electrophoretic studies of human plasma cryoprecipitates with a high content of antihemophilic globulin A].
Kleint V; Wegner H
Z Gesamte Inn Med; 1970 Apr; 25(7):312-4. PubMed ID: 5521442
[No Abstract] [Full Text] [Related]
13. The development of plasma derivatives in Canada.
McVicar GA
Vox Sang; 1972; 23(1):33-4. PubMed ID: 4117046
[No Abstract] [Full Text] [Related]
14. Optimal use of blood components and derivatives.
Walter WJ; Oberman HA
Otolaryngol Clin North Am; 1981 Aug; 14(3):739-53. PubMed ID: 6795570
[No Abstract] [Full Text] [Related]
15. Round table discussion on plasma fractionation.
Vox Sang; 1972; 23(1):61-5. PubMed ID: 5081015
[No Abstract] [Full Text] [Related]
16. What is the importance of the 'small pool concept' in the preparation of fraciton I and cryoprecipitates for the prevention of post-transfusion hepatitis?
Vox Sang; 1980 Feb; 38(2):106-19. PubMed ID: 6773242
[No Abstract] [Full Text] [Related]
17. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
Prowse CV; Griffin B; Pepper DS; Dickson AJ; McQuillan TA; Dickson IH; Foster PR
Thromb Haemost; 1981 Oct; 46(3):597-601. PubMed ID: 6797090
[TBL] [Abstract][Full Text] [Related]
18. Plasma fractionation in blood transfusion service.
Haskó F; Salamon M; Bartha K; Dobó P
Dev Biol Stand; 1987; 67():39-48. PubMed ID: 3111912
[TBL] [Abstract][Full Text] [Related]
19. Microwave-thawed plasma for cryoprecipitate production.
Bass H; Trenchard PM; Mustow MJ
Vox Sang; 1985; 48(2):65-71. PubMed ID: 3934842
[TBL] [Abstract][Full Text] [Related]
20. [A new human factor VIII concentrate. Preparation and clinical use].
Simonetti C; Casillas G; Farías C; De los Santos JC
Medicina (B Aires); 1981; 41 Suppl():249-52. PubMed ID: 6808288
[No Abstract] [Full Text] [Related]
[Next] [New Search]
